Real-World 52-Week Effectiveness Study of Deucravacitinib in Psoriasis Background Introduction Psoriasis is a chronic inflammatory skin disease with a global prevalence of approximately 1% to 3%. This condition not only affects patients’ quality of life (QoL) but is also often accompanied by comorbidities such as cardiovascular diseases, diabetes, ...